FcGR3A (CD16A) CHO Cell Line

Catalog #
78332
$7,150 *
Size: 2 vials
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Recombinant CHO cell line stably expressing full length human CD16A (also known as FCGR3A, FcγRIIIa; ref. seq. NM_ 000569.8) under the control of the CMV promoter.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

Synonyms
Low affinity immunoglobulin gamma Fc region receptor III-A, CD16a antigen, Fc-gamma RIII-alpha, FcR-10, IgG Fc receptor III-2, CD_antigen: CD16a, FcGR-3A, FcγRIIIA, FCGRIIIA
Product Info
Storage and Usage
Citations
Host Cell Line
CHO-K1, Chinese Hamster Ovary, epithelial-like cells, adherent
Species
Human
Supplied As
Each vial contains 2 x 106 cells in 1 ml of 10% DMSO
Materials Required But Not Supplied
Name Ordering Information
Thaw Medium 3 BPS Bioscience #60186
Growth Medium 3J BPS Bioscience #79974
Formulation

For best results, it is highly recommended to use these validated and optimized media from BPS Bioscience. Other preparations or formulations of media may result in suboptimal performance. 

Thaw Medium 3 (BPS Bioscience #60186):
F-12K Medium (Kaighn's Modification of Ham's F-12 Medium) supplemented with 10% FBS, 1% Penicillin/Streptomycin

Growth Medium 3J (BPS Bioscience #79974):
F-12K Medium (Kaighn's Modification of Ham's F-12 Medium) supplemented with 10% FBS, 1% Penicillin/Streptomycin plus 5 μg/ml of Puromycin

Genbank #
NM_ 000569.8
UniProt #
P08637
Mycoplasma Testing

The cell line has been screened to confirm the absence of Mycoplasma species.

Background

Fc Gamma Receptor 3A (FcGRIIIA; FcγRIIIA), also known as CD16A, is a low/intermediate affinity receptor for polyvalent immune-complexed IgG. It is involved in phagocytosis, antibody-dependent cytotoxicity, and clearance of immune complexes. The human FcGR3A displays a dimorphism at residue 158. One allele (V158) encodes a higher Fc affinity receptor variant with a valine at amino acid residue 158 while the other allele (F158) encodes a lower Fc affinity receptor variant having a phenylalanine at amino acid residue 158.

FcGR3A (CD16A) plays a role in the activation of natural killer (NK) cells. Clinically, it serves as a marker of certain immune cells such as neutrophils. Its expression has been observed at the surface of T cells in patients with chronic viral infections (such as COVID-19). It is considered a potential therapeutic target to potentiate the efficacy of therapeutic antibodies used to treat solid tumors, or as direct target in hematopoietic cancers.